Name: Brain Metastases of Breast Cancer (en Inglés)
Price: 76920.00 CLP
Availability: InStock
Author: Wala Ben Kridis; Afef Khanfir
ISBN: 9786205731611

portada Brain Metastases of Breast Cancer (en Inglés)

Formato

Libro Físico

Editorial

Our Knowledge Publishing

Autor

Wala Ben Kridis; Afef Khanfir

Idioma

Inglés

N° páginas

Encuadernación

Tapa Blanda

ISBN13

9786205731611

Brain Metastases of Breast Cancer (en Inglés)

Wala Ben Kridis; Afef Khanfir (Autor) · Our Knowledge Publishing · Tapa Blanda

Libro Físico

$ 76.920

$ 106.840

Ahorras: $ 29.920

28% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Lunes 15 de Julio y el Lunes 22 de Julio.

Lo recibirás en cualquier lugar de Chile entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Brain Metastases of Breast Cancer (en Inglés)"

Breast cancer is the first cancer of women in the world and in Tunisia with an incidence of 46.3 and 37.8 cases / 100 000 inhabitants per year respectively. It is the second cause of cancer mortality in women in Tunisia with 17 deaths / 100 000 inhabitants per year.The management of metastatic breast cancer has undergone several advances over the past decades leading to an improvement in patient survival. However, 15 to 30% of patients will develop brain metastases (BM) during their disease. They can occur synchronously (at the time of diagnosis of the primary cancer) or metachronously (after 6 months of the end of the primary cancer treatment). The management of CD is multidisciplinary, involving neurologists, neurosurgeons, radiologists, radiation oncologists, medical oncologists and pathologists.Radiation therapy (RT) is one of the pillars of CD treatment and has long been the standard treatment with its different modalities.The place of surgery is discussed according to the operability and resectability of metastases, as well as the status of systemic disease.Systemic treatment can be based on chemotherapy, hormonal therapy and targeted therapy and depends on the terrain, molecular classification and previously prescribed treatments.